The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

Sino Biopharmaceuticals plans to pay up to nearly $951 million to acquire LaNova Medicines, which previously licensed drugs ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...

Protein degraders: chasing undruggable targets Biotech and pharma companies are searching for ways to “hijack” the cell’s waste disposal systems in hopes of making more effective drugs.

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" ...

The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...